Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilunocadase
- Development stage
- Unknown
- Lead developer
- AM-Pharma
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Ilunocadase (also known as recAP) is a recombinant human alkaline phosphatase developed by AM-Pharma for the treatment of sepsis-associated acute kidney injury (SA-AKI). The drug is a dephosphorylating enzyme that functions by neutralizing extracellular pro-inflammatory mediators such as lipopolysaccharide (LPS) and adenosine triphosphate (ATP), which are released during infection and cellular stress. By detoxifying these molecules, ilunocadase aims to reduce systemic inflammation and protect the renal microenvironment from damage. While early studies utilized bovine intestinal alkaline phosphatase (bIAP), AM-Pharma transitioned to the recombinant human version for clinical development. Despite reaching Phase 3 trials (REVIVAL study), the program faced challenges when the primary endpoint was not met in certain populations, though development in related indications continues.
- Other names
- recombinant human alkaline phosphatasebovine intestinal alkaline phosphatasealkaline phosphatasetislelizumab + cisplatin + gemcitabine + trilaciclib-AM-Pharma-sepsis-acute kidney injury
02
Targets
Lipopolysaccharide (LPS) phosphate groups
Beyond the preview
Go deeper on ilunocadase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilunocadase.